# Methadone Dose and Patient-Directed Discharge in Hospitalized Patients With Opioid Use Disorder

**Authors:** Rebecca R. Meredith, William M. Garneau, Kenneth A. Feder, Megan E. Buresh

PMC · DOI: 10.1001/jamanetworkopen.2026.3439 · 2026-03-25

## TL;DR

Higher early doses of methadone in hospitalized patients with opioid use disorder are linked to lower chances of leaving the hospital before treatment is complete.

## Contribution

The study identifies a novel association between early methadone dosing and reduced patient-directed discharge in opioid use disorder patients.

## Key findings

- Higher methadone doses in the first 24 hours were linked to lower odds of patient-directed discharge.
- Adjusted odds ratios showed significant reductions in discharge across multiple time points with increased methadone dosing.
- Results suggest early methadone treatment may improve retention in hospitalized opioid use disorder patients.

## Abstract

This cohort study investigates the association of higher early doses of methadone with odds of patient-directed discharge among hospitalized patients with opioid use disorder.

Among hospitalized patients with opioid use disorder, is there an association between the early cumulative dose of methadone and risk of patient-directed discharge?

In this cohort study of 554 adults with opioid use disorder who were admitted to the hospital and received methadone during the first 72 hours, there was a decreased risk of patient-directed discharge with increased methadone dose given during the first 24 hours of care in an adjusted analysis.

These findings suggest that in the fentanyl era, early treatment with a higher cumulative dose of methadone may be associated with reduced patient-directed discharge.

Patient-directed discharge (PDD), when patients leave the hospital prior to completing recommended medical treatment, is associated with increased morbidity and mortality and occurs in 10% to 20% of hospitalizations for patients with opioid use disorder (OUD). Understanding risk factors associated with PDD is essential to improving outcomes for this population.

To investigate whether hospitalized patients with OUD who received higher doses of methadone during the first 24, 48, and 72 hours after first contact with the emergency department had decreased odds of PDD.

This retrospective observational cohort study was conducted at a single academic health center in the northeastern US during the fentanyl era (July 1, 2019, to June 30, 2022). Hospitalized adults with OUD and without methadone listed in their medication history who received methadone during the first 72 hours were included. Data were analyzed from April 2025 through February 2026.

Cumulative dose of methadone received for patients 24, 48, and 72 hours after initial evaluation in the emergency department.

PDD by 48, 72, or 96 hours or ever, as indicated by discharge disposition in the patient electronic health record.

A total of 554 patients were included in the study. For analysis, participants were separated into cohorts based on cumulative dose by 24 hours (325 patients), 48 hours (488 patients), and 72 hours (454 patients) after presentation to the emergency department, with the main analysis among patients in the 24-hour cohort. Among 325 patients (184 male [56.6%]; median [IQR] age, 49.0 [36.0-59.0] years) receiving methadone within 24 hours of presentation to the emergency department, the incidence of PDD was 45 patients (13.8%). In an adjusted logistic regression model, each additional 10 mg of methadone in the first 24 hours was associated with lower odds of PDD (adjusted odds ratio [aOR], 0.71; 95% CI, 0.44-0.98) at 48 hours. Results were similar for PDD at 72 hours (aOR, 0.68; 95% CI, 0.50-0.85), 96 hours (aOR, 0.72; 95% CI, 0.56-0.88), or ever (aOR, 0.79; 95% CI, 0.67-0.91) in the 24-hour cohort and qualitatively similar but with smaller decreases in odds or nonsignificant outcomes for cumulative methadone dose in the 48-hour cohort (eg, PDD at 96 hours: aOR, 0.91; 95% CI, 0.82-0.99) and nonsignificant outcomes in the 72-hour cohort (eg, PDD at 96 hours: aOR, 0.98; 95% CI, 0.89-1.06).

In this study, higher cumulative doses of methadone during the first 48 hours of care were associated with substantial reductions in the incidence of PDD. These findings suggest that early and adequate treatment of withdrawal with methadone may be associated with reduced PDD among hospitalized patients with OUD in the fentanyl era.

## Linked entities

- **Chemicals:** methadone (PubChem CID 4095)

## Full-text entities

- **Diseases:** PDD (MESH:D019522), pain (MESH:D010146), stimulant use disorder (MESH:D000437), addiction (MESH:D019966), drug overdoses (MESH:D062787), opioid analgesia (MESH:D000699), MOUD (MESH:D009293)
- **Chemicals:** Methadone (MESH:D008691), heroin (MESH:D003932), MOUD (-), Fentanyl (MESH:D005283), morphine (MESH:D009020), buprenorphine (MESH:D002047)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13019229/full.md

---
Source: https://tomesphere.com/paper/PMC13019229